European Medicines Agency Approves Positive Opinion on Omeros' Pediatric Investigation Plan for OMS302

   European Medicines Agency Approves Positive Opinion on Omeros' Pediatric
                        Investigation Plan for OMS302

-- Submission of Marketing Authorization Application Remains on Track for
Mid-Year--

PR Newswire

SEATTLE, July 2, 2013

SEATTLE, July 2, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER) today
announced that the European Medicines Agency (EMA) approved a positive opinion
issued by the European Pediatrics Committee (PDCO) agreeing to the Company's
Pediatric Investigation Plan (PIP) for OMS302. EMA's approval of PDCO's
positive opinion is a prerequisite for submission of the OMS302 Marketing
Authorization Application (MAA) and, on completion of the post-marketing
pediatric study, leads to an additional six months of patent exclusivity for
OMS302 in Europe. OMS302, added to standard irrigation solution used during
ophthalmological procedures, is Omeros' proprietary PharmacoSurgery™ product
designed to maintain intraoperative mydriasis (pupil dilation), prevent
surgically induced miosis (pupil constriction), and reduce postoperative pain
resulting from cataract and other lens replacement surgery.

Omeros' PIP provides a study plan to evaluate the drug's safety and efficacy
in patients 13-17 years old. Omeros received a waiver for studying the use of
OMS302 in patients younger than 13 years and a deferral to complete the
clinical study following EMA approval. With completion of the study as
specified under the PIP, Omeros will be eligible to receive an additional six
months of marketing exclusivity for OMS302 in the European Union (E.U.). This
six-month period would extend beyond the expiration of Omeros' patents
directed to OMS302, which will expire in the E.U. in 2023 for issued patents
and 2033 for patents expected to issue from currently pending patent
applications. This six-month extension is in addition to a supplementary
protection certificate, which together could provide up to another five and
one half years of market exclusivity for OMS302. Omeros is pursuing a similar
but separate process in the U.S. for studying the use of OMS302 in pediatric
patients, which is expected to lead to additional marketing exclusivity in the
U.S. Submission of the New Drug Application (NDA) for OMS302 in the U.S. will
precede the MAA submission, and both applications will include additional
stability data to extend expiry dating at the time of expected commercial
launch.

"Although cataract surgery in pediatric patients is uncommon, we expect that
OMS302 will provide similar benefits to those that we have seen in adults
undergoing lens replacement," stated Gregory A. Demopulos, M.D., chairman and
chief executive officer of Omeros. "We will gain important clinical
information from the PIP study and, once completed, we expect to receive an
additional six months of European marketing exclusivity. With agreement from
the EMA on our pediatric plan, we remain on schedule for a mid-year submission
of the OMS302 MAA, and we look forward to providing European ophthalmic
surgeons and their patients access to the drug in 2014."

About Omeros' OMS302 Program
OMS302 is Omeros' product being developed for use during intraocular lens
replacement (ILR), including cataract surgery and refractive lens exchange.
OMS302 is a proprietary combination of the mydriatic (pupil dilating) agent
phenylephrine and the anti-inflammatory agent ketorolac. Omeros recently
completed its successful OMS302 Phase 3 clinical program and expects to submit
a New Drug Application to the U.S. Food and Drug Administration this quarter
and a Marketing Authorization Application to the European Medicines Agency in
mid-2013.

ILR involves replacement of the original lens of the eye with an artificial
intraocular lens. These procedures are typically performed to replace a lens
opacified by a cataract or to correct a refractive error of the lens (i.e.,
refractive lens exchange). OMS302 is added to standard irrigation solution
used in ILR and delivered within the eye to maintain intraoperative mydriasis
(pupil dilation), to reduce surgically induced miosis (pupil constriction),
and to reduce postoperative pain and irritation. Maintenance of mydriasis is
critical to the safety and surgical ease of the procedure. Intraoperative
pupil constriction increases the risk of injury to intraocular structures and
can substantially prolong surgical time.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing products targeting inflammation, coagulopathies
and disorders of the central nervous system. The Company's most clinically
advanced product candidates, OMS302 for lens replacement surgery and OMS103HP
for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform
designed to improve clinical outcomes of patients undergoing a wide range of
surgical and medical procedures. Omeros has five clinical development
programs. Omeros may also have the near-term capability, through its GPCR
program, to add a large number of new drug targets and their corresponding
compounds to the market. Behind its clinical candidates and GPCR platform,
Omeros is building a diverse pipeline of protein and small-molecule
preclinical programs targeting inflammation, coagulopathies and central
nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the
Private Securities Litigation Reform Act of 1995, which are subject to the
"safe harbor" created by those sections. These statements include, but are not
limited to, Omeros' expectations regarding its plans to complete the Pediatric
Investigation Plan; potential market exclusivities for OMS302; the potential
clinical benefits of OMS302; the timing for submission of a New Drug
Application for OMS302 to the U.S. FDA and a Marketing Authorization
Application for OMS302 to the European Medicines Agency; potential OMS302
marketing approval; and that Omeros may have capability, through its GPCR
program, to add a large number of new drug targets and their corresponding
compounds to the market. Forward-looking statements are based on management's
beliefs and assumptions and on information available to management only as of
the date of this press release. Omeros' actual results could differ materially
from those anticipated in these forward-looking statements for many reasons,
including, without limitation, the risks, uncertainties and other factors
described under the heading "Risk Factors" in the Company's Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2013.
Given these risks, uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and the Company assumes no
obligation to update these forward-looking statements publicly, even if new
information becomes available in the future.

SOURCE Omeros Corporation

Contact: Jennifer Cook Williams, Cook Williams Communications, Inc., Investor
and Media Relations, +1-360-668-3701, jennifer@cwcomm.org
 
Press spacebar to pause and continue. Press esc to stop.